1. Fratiglioni L, De Ronchi D, Aguero-Torres H. Worldwide prevalence and incidence of dementia. Drugs Aging. 1999; 15:365–375.
2. Gao L, Liu Y, Li X, et al. Abnormal retinal nerve fiber layer thickness and macula lutea in patients with mild cognitive impairment and Alzheimer's disease. Arch Gerontol Geriatr. 2015; 60:162–167.
3. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991; 82:239–259.
4. Leuba G, Saini K. Pathology of subcortical visual centres in relation to cortical degeneration in Alzheimer's disease. Neuropathol Appl Neurobiol. 1995; 21:410–422.
5. Hof PR, Vogt BA, Bouras C, Morrison JH. Atypical form of Alzheimer's disease with prominent posterior cortical atrophy: a review of lesion distribution and circuit disconnection in cortical visual pathways. Vision Res. 1997; 37:3609–3625.
6. Blanks JC, Torigoe Y, Hinton DR, Blanks RH. Retinal pathology in Alzheimer's disease. I. Ganglion cell loss in foveal/parafoveal retina. Neurobiol Aging. 1996; 17:377–384.
7. Trick GL, Trick LR, Morris P, Wolf M. Visual field loss in senile dementia of the Alzheimer's type. Neurology. 1995; 45:68–74.
8. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999; 56:303–308.
9. Kelley BJ, Petersen RC. Alzheimer's disease and mild cognitive impairment. Neurol Clin. 2007; 25:577–609.
10. Levey A, Lah J, Goldstein F, et al. Mild cognitive impairment: an opportunity to identify patients at high risk for progression to Alzheimer's disease. Clin Ther. 2006; 28:991–1001.
11. Werner P, Korczyn AD. Mild cognitive impairment: conceptual, assessment, ethical, and social issues. Clin Interv Aging. 2008; 3:413–420.
12. Petersen RC, Stevens JC, Ganguli M, et al. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001; 56:1133–1142.
13. Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment: beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004; 256:240–246.
14. Petersen RC, Roberts RO, Knopman DS, et al. Mild cognitive impairment: ten years later. Arch Neurol. 2009; 66:1447–1455.
15. Morris JC, Cummings J. Mild cognitive impairment (MCI) represents early-stage Alzheimer's disease. J Alzheimers Dis. 2005; 7:235–239.
16. Markesbery WR, Schmitt FA, Kryscio RJ, et al. Neuropathologic substrate of mild cognitive impairment. Arch Neurol. 2006; 63:38–46.
17. Ikram MK, Cheung CY, Wong TY, Chen CP. Retinal pathology as biomarker for cognitive impairment and Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2012; 83:917–922.
18. Hinton DR, Sadun AA, Blanks JC, Miller CA. Optic-nerve degeneration in Alzheimer's disease. N Engl J Med. 1986; 315:485–487.
19. Jaffe GJ, Caprioli J. Optical coherence tomography to detect and manage retinal disease and glaucoma. Am J Ophthalmol. 2004; 137:156–169.
20. Hassenstein A, Spital G, Scholz F, et al. Optical coherence tomography for macula diagnostics. Review of methods and standardized application concentrating on diagnostic and therapy control of age-related macula degeneration. Ophthalmologe. 2009; 106:116–126.
21. Ratchford JN, Quigg ME, Conger A, et al. Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies. Neurology. 2009; 73:302–308.
22. Hajee ME, March WF, Lazzaro DR, et al. Inner retinal layer thinning in Parkinson disease. Arch Ophthalmol. 2009; 127:737–741.
23. Ascaso FJ, Cabezon L, Quintanilla MA, et al. Retinal nerve fiber layer thickness measured by optical coherence tomography in patients with schizophrenia: a short report. Eur J Psychiatry. 2010; 24:227–235.
24. Parisi V, Restuccia R, Fattapposta F, et al. Morphological and functional retinal impairment in Alzheimer's disease patients. Clin Neurophysiol. 2001; 112:1860–1867.
25. Iseri PK, Altinas O, Tokay T, Yuksel N. Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease. J Neuroophthalmol. 2006; 26:18–24.
26. Berisha F, Feke GT, Trempe CL, et al. Retinal abnormalities in early Alzheimer's disease. Invest Ophthalmol Vis Sci. 2007; 48:2285–2289.
27. Paquet C, Boissonnot M, Roger F, et al. Abnormal retinal thickness in patients with mild cognitive impairment and Alzheimer's disease. Neurosci Lett. 2007; 420:97–99.
28. Kesler A, Vakhapova V, Korczyn AD, et al. Retinal thickness in patients with mild cognitive impairment and Alzheimer's disease. Clin Neurol Neurosurg. 2011; 113:523–526.
29. Cheung CY, Ong YT, Hilal S, et al. Retinal ganglion cell analysis using high-definition optical coherence tomography in patients with mild cognitive impairment and Alzheimer's disease. J Alzheimers Dis. 2015; 45:45–56.
30. Kirbas S, Turkyilmaz K, Anlar O, et al. Retinal nerve fiber layer thickness in patients with Alzheimer disease. J Neuroophthalmol. 2013; 33:58–61.
31. Liu D, Zhang L, Li Z, et al. Thinner changes of the retinal nerve fiber layer in patients with mild cognitive impairment and Alzheimer's disease. BMC Neurol. 2015; 15:14.
32. Blanks JC, Schmidt SY, Torigoe Y, et al. Retinal pathology in Alzheimer's disease. II. Regional neuron loss and glial changes in GCL. Neurobiol Aging. 1996; 17:385–395.
33. Lamirel C, Newman N, Biousse V. The use of optical coherence tomography in neurology. Rev Neurol Dis. 2009; 6:E105–E120.
34. Sakata LM, Deleon-Ortega J, Sakata V, Girkin CA. Optical coherence tomography of the retina and optic nerve: a review. Clin Exp Ophthalmol. 2009; 37:90–99.
35. Portet F, Ousset PJ, Visser PJ, et al. Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's Disease. J Neurol Neurosurg Psychiatry. 2006; 77:714–718.
36. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (IV-TR). 4th ed. Washington, DC: American Psychiatric Association;2000. p. 413–435.
37. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003; 2:605–613.
38. Galasko D. Biomarkers for Alzheimer's disease: clinical needs and application. J Alzheimers Dis. 2005; 8:339–346.
39. He XF, Liu YT, Peng C, et al. Optical coherence tomography assessed retinal nerve fiber layer thickness in patients with Alzheimer's disease: a meta-analysis. Int J Ophthalmol. 2012; 5:401–405.
40. Frohman EM, Fujimoto JG, Frohman TC, et al. Optical coherence tomography: a window into the mechanisms of multiple sclerosis. Nat Clin Pract Neurol. 2008; 4:664–675.
41. Chi Y, Wang YH, Yang L. The investigation of retinal nerve fiber loss in Alzheimer's disease. Zhonghua Yan Ke Za Zhi. 2010; 46:134–139.
42. Schmidtke K, Hermeneit S. High rate of conversion to Alzheimer's disease in a cohort of amnestic MCI patients. Int Psychogeriatr. 2008; 20:96–108.
43. Ascaso FJ, Cruz N, Modrego PJ, et al. Retinal alterations in mild cognitive impairment and Alzheimer's disease: an optical coherence tomography study. J Neurol. 2014; 261:1522–1530.
44. Feuer WJ, Budenz DL, Anderson DR, et al. Topographic differences in the age-related changes in the retinal nerve fiber layer of normal eyes measured by Stratus optical coherence tomography. J Glaucoma. 2011; 20:133–138.
45. Shi Z, Wu Y, Wang M, et al. Greater attenuation of retinal nerve fiber layer thickness in Alzheimer's disease patients. J Alzheimers Dis. 2014; 40:277–283.
46. Shen Y, Liu L, Cheng Y, et al. Retinal nerve fiber layer thickness is associated with episodic memory deficit in mild cognitive impairment patients. Curr Alzheimer Res. 2014; 11:259–266.